HYPDH inhibitors and methods of use for the treatment of kidney stones

Patent metadata

Field	Value
Publication number	US-10562844-B2
Application number	US-201615545818-A
Country	US
Kind code	B2
Filing date	Jan 25, 2016
Priority date	Jan 26, 2015
Publication date	Feb 18, 2020
Grant date	Feb 18, 2020

Abstract

Provided herein are compounds of Formula (I), Formula (II), and Formula (III), and compositions comprising the same, as well as methods of use thereof for controlling or inhibiting the formation of calcium oxalate kidney stones, inhibiting the production of glyoxylate and/or oxalate, and/or inhibiting hydroxyproline dehydrogenase (HYPDH).

First claim

That which is claimed is:

1. A method of inhibiting the formation of oxalate kidney stones, comprising: administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I:

wherein:
X is O, or CR x R y , wherein R x and R y are each;
n is 0, 1, 2, 3, 4, 5 or 6;
R 1 is carboxy;
R 2 is selected from the group consisting of: H, alkyl, hydroxy, amine, and ═O; or R 2 is R 2a R 2b , wherein R 2a and R 2b are each independently selected from alkyl and hydroxy;
R 3 is selected from the group consisting of: H, hydroxy, amine, and ═O; or R 3 is R 3a R 3b , wherein R 3a and R 3b are each hydroxy; and
R 4 is selected from the group consisting of: H, alkyl, and hydroxy; or R 4 is R 4a R 4b wherein R 4a and R 4b are each independently selected from alkyl, hydroxy, and halo, wherein said alkyl may be unsubstituted or substituted 1, 2 or 3 times with hydroxy;
or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 ,
wherein:
X is S;
n is O;
R 2 is selected from the group consisting of: H and lower alkyl;
R 3 is selected from the group consisting of: hydroxy, and ═O; or R 3 is R 3a R 3b , wherein R 3a and R 3b are each hydroxy; and
R 4 is selected from the group consisting of: H and lower alkyl;
or a pharmaceutically acceptable salt thereof.

3. A method of inhibiting the production of glyoxylate and/or oxalate in a subject in need thereof, comprising: administering to said subject a therapeutically effective amount of a compound of Formula I:

wherein:
X is O, S or CR x R y , wherein R x and R y are each H;
n is 0, 1, 2, 3, 4, 5 or 6;
R 1 is carboxy;
R 2 is selected from the group consisting of: H, alkyl, hydroxy, amine, and ═O; or R 2 is R 2a R 2b , wherein R 2a and R 2b are each independently selected from alkyl and hydroxy;
R 3 is selected from the group consisting of: H, hydroxy, amine, and ═O; or R 3 is R 3a R 3b , wherein R 3a and R 3b are each hydroxy; and
R 4 is selected from the group consisting of: H, alkyl, and hydroxy; or R 4 is R 4a R 4b wherein R 4a and R 4b are each independently selected from alkyl, hydroxy, and halo, wherein said alkyl may be unsubstituted or substituted 1, 2 or 3 times with hydroxy;
or a pharmaceutically acceptable salt thereof.

4. The method of claim 3 ,
wherein:
X is S;
n is O;
R 2 is selected from the group consisting of: H and lower alkyl;
R 3 is selected from the group consisting of: H, hydroxy, and ═O; or R 3 is R 3A R 3b , wherein R 3a and R 3b are each hydroxy; and
R 4 is selected from the group consisting of: H and lower alkyl;
or a pharmaceutically acceptable salt thereof.

5. A method of inhibiting hydroxyproline dehydrogenase (HYPDH) in a subject in need thereof, comprising: administering to said subject a therapeutically effective amount of a compound of Formula I:

wherein:
X is O, S or CR x R y , wherein R x and R y are each H;
n is 0, 1, 2, 3, 4, 5 or 6;
R 1 is carboxy;
R 2 is selected from the group consisting of: H, alkyl, hydroxy, amine, and ═O; or R 2 is R 2a R 2b , wherein R 2a and R 2b are each independently selected from alkyl and hydroxy;
R 3 is selected from the group consisting of: H, hydroxy, amine, and ═O; or R 3 is R 3a R 3b , wherein R 3a and R 3b are each hydroxy; and
R 4 is selected from the group consisting of: H, alkyl, and hydroxy; or R 4 is R 4a R 4b wherein R 4a and R 4b are each independently selected from alkyl, hydroxy, and halo, wherein said alkyl may be unsubstituted or substituted 1, 2 or 3 times with hydroxy;
or a pharmaceutically acceptable salt thereof.

6. The method of claim 5 ,
wherein:
X is S;
n is 0;
R 1 is carboxy;
R 2 is selected from the group consisting of: H and lower alkyl;
R 3 is selected from the group consisting of: H, hydroxy, and ═O; or R 3 is R 3a R 3b , wherein R 3a and R 3b are each hydroxy; and
R 4 is selected from the group consisting of: H and lower alkyl;
or a pharmaceutically acceptable salt thereof.

7. The method of claim 1 , wherein said compound is selected from the group consisting of:

and pharmaceutically acceptable salts thereof.

8. The method of claim 1 , wherein said compound is selected from the group consisting of:

and pharmaceutically acceptable salts thereof.

9. The method of claim 1 , wherein said compound is selected from the group consisting of:

and pharmaceutically acceptable salts thereof.

10. The method of claim 1 , wherein said subject is a human subject.

11. The method of claim 1 , wherein said subject is a non-human animal subject.

12. The method of claim 1 , wherein said administering is carried out by administering a pharmaceutical composition comprising said compound or pharmaceutically acceptable salt thereof.

13. The method of claim 3 , wherein said subject is a human subject.

14. The method of claim 3 , wherein said subject is a non-human animal subject.

15. The method of claim 3 , wherein said administering is carried out by administering a pharmaceutical composition comprising said compound or pharmaceutically acceptable salt thereof.

16. The method of claim 5 , wherein said subject is a human subject.

17. The method of claim 5 , wherein said subject is a non-human animal subject.

18. The method of claim 5 , wherein said administering is carried out by administering a pharmaceutical composition comprising said compound or pharmaceutically acceptable salt thereof.

Assignees

• Univ Wake Forest Health Sciences
• Uab Research Foundation

Inventors

• Lowther W Todd
• Holmes Ross P
• Yohannes Daniel

Classifications

• C07D307/68

  Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen · CPC title

• C07D333/38

  Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals · CPC title

• C07D233/90

  Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals · CPC title

• C07D307/24

  Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen · CPC title

• C07C62/24

  the keto group being part of a ring · CPC title